Quick Answer: To sell cosmetics in New Zealand, first confirm the product category and intended claims, identify the importing or manufacturing business, review the current EPA cosmetic rules, and match the formula to the final label. Build a controlled supplier evidence file and approve the actual commercial batch before shipment. The 2026 rule changes require a current review rather than reliance on an older overseas launch.
MOOYAM editorial content. Last reviewed: 14 October 2026. Cover: AI-generated editorial illustration.
Start with a launch brief that can be reviewed
A New Zealand launch becomes manageable when a brand converts its commercial idea into a specific product brief. Record the format, intended users, application area, directions, pack sizes, proposed claims and sales channels. Include the formula version and manufacturer contact. A cleanser sold to adults through a web shop and a specialist product presented for a medical purpose need different questions answered, even when both arrive in attractive skincare packaging.
Keep the brief useful for the people making decisions. The person reviewing compliance should see the same claims that customers will read. The factory should receive the exact packaging and performance requirements. The importing business should know the intended shipment timing and the person authorised to release stock. A presentation assembled only after production is complete makes unresolved questions harder to correct.
This guide concerns an ordinary cosmetic launch workflow. It does not decide the category of an individual product. For the framework behind the launch, read a neighbouring-market compliance planning guide. For a technical screening project, use an example of ingredient evidence planning for Australia.
Confirm the category before buying production
The Medsafe product categorisation guidance explains that composition, intended purpose and market presentation determine the category. Therapeutic claims are not permitted for products supplied as cosmetics. Review packaging, web copy, testimonials and influencer material together. A claim introduced by a sales partner can change the presentation customers receive even if the manufacturer never printed it on the carton.
Prepare a claims register with three fields: proposed wording, available support and review outcome. Include images and context where they influence the message. Ask the reviewer to identify any unresolved category question before artwork sign-off. If a product sits near a medicines boundary, obtain an appropriate categorisation assessment rather than guessing from the product name.
Practical commercial claims review also prevents avoidable rework. Do not promise a therapeutic result because a raw material brochure describes a biological mechanism. Evidence for an ingredient is not automatically evidence for the finished formula under its advertised use. Agree the wording that can be supported by the actual product and the market-specific assessment.
| Workstream | Official source | Review question |
|---|---|---|
| Cosmetic composition | EPA cosmetic group standard | Which current conditions apply to this formula? |
| Product categorisation | Medsafe guidance | What do ingredients, purpose and claims imply? |
| Commercial implementation | Assigned project parties | Who holds evidence and approves release? |
Use the current New Zealand rules in the purchase decision
The EPA updated cosmetic rules guidance confirms that the revised group standard took effect on 1 January 2026, with further transitions extending into 2029. Its scope now includes a non-hazardous finished cosmetic containing a hazardous ingredient. An earlier assessment based only on the finished mixture being non-hazardous therefore needs reconsideration.
Ask the reviewer to use the current legal instrument and record the version assessed. The public guidance is an accessible starting point, but EPA identifies the group standard as the source of the full rules. This article does not provide a substance-by-substance approval list. Supplier assurances should be tied to the formula and relevant New Zealand conditions.
Schedule stock planning around the applicable transition category. General non-compliant stock, PFAS-containing cosmetics and products with more than 10% homosalate have different dates. Do not apply one sell-through deadline to every SKU. Capture the reviewer’s conclusion in the purchasing file before fixing shipment quantities or committing to retailer promotions.
Create an evidence handover with the manufacturer
A manufacturer can supply agreed technical inputs: controlled formula information, ingredient identities, relevant specifications, COA and SDS, batch references, and available stability or microbiological information. Ask what is already available and what must be generated for the project. A catalogue phrase such as “export quality” is too broad to identify the evidence a New Zealand reviewer needs.
Where a full quantitative formula is confidential, agree a protected disclosure route to the appointed reviewer. The aim is enough detail to assess the actual product, not circulation of proprietary information among unrelated commercial contacts. Record which formula version the reviewer received, when any missing supplier statement arrived, and who can answer further questions.
Use private label skincare manufacturing discussions to align the product brief with the technical handover. Ask for a written list of deliverables before a purchase order. Distinguish factory documents from the local business’s review conclusions so a missing responsibility does not disappear between the two teams.
| Input | Purpose | Suggested owner |
|---|---|---|
| Controlled formula and raw-material identities | Enable composition screening | Manufacturer and suppliers |
| Intended use and complete claims | Support category assessment | Brand and local reviewer |
| Current-rule conclusion | Record applicable conditions and dates | Relevant New Zealand party and reviewer |
| Final artwork and batch reference | Connect assessment to commercial stock | Brand and manufacturer |
Freeze packaging only after the formula and claims align
Build an artwork checklist from the applicable assessment. Link the ingredient declaration, directions, warnings and commercial identity to the approved formula. Check every pack size and promotional variation. A small travel pack may have different space constraints from a full-size carton, but it still needs a deliberate readability and information review.
Run a proof comparison between the approved digital artwork and the actual printed sample. Look for missing lines, changed symbols, altered ingredient spelling and supplier substitutions. Confirm the bottle and outer carton belong to the same formula and batch specification. Photographs of the signed proof are useful operational records, but they do not establish statutory approval.
Have someone outside the artwork team read the pack under ordinary viewing conditions. On an online product page, inspect the mobile version and the product images customers can enlarge. This practical check helps identify contradictions between printed instructions and the website before a customer uses the product.
Set the release and stock-control workflow
The launch owner should maintain a release checklist with open issues, assigned contacts and documentary references. Do not turn every item into an assumed mandatory test: the appropriate testing and evidence depend on the formula, packaging, intended use and applicable assessment. Record the reason for each requirement so the team understands what a passing result answers.
Before shipment, match the commercial batch to the approved version. A fragrance substitution, preservative change or new raw-material grade should trigger the agreed change-control process. Ask the supplier to notify the brand before implementing changes, including changes described internally as equivalent. An ingredient declaration alone may not reveal a changed concentration or relevant impurity profile.
After launch, keep complaints, returns and batch identification connected. Decide who can pause sales, retrieve technical records and coordinate a corrective response. Review new claims before adding them to ads or product pages. A launch file remains useful only when it follows the product’s actual manufacturing and commercial history.
How MOOYAM can support the project
MOOYAM can discuss OEM/ODM production, product development, packaging options and the technical documentation available for the agreed project. Share the target product category, commercial positioning, proposed claims and the reviewer’s evidence requests early. That gives the manufacturing team a concrete brief and helps identify work needed before the production schedule is fixed.
Use the MOOYAM contact page to start a project discussion. Ask for the scope of manufacturing support in writing. The brand and relevant New Zealand parties should separately assign local classification, legal review and market administration responsibilities. Manufacturing support is most effective when those decisions have a clear owner.
Frequently asked questions
Do ordinary cosmetics need a universal New Zealand approval certificate?
Do not assume there is one certificate that resolves every product, formula and claim. Identify the applicable category and EPA requirements, then obtain a documented assessment for the actual product.
Can an overseas compliant formula be sold unchanged?
An overseas review is useful background, but the New Zealand conditions and current version of the rules must be checked. Ask the reviewer to identify any reformulation or packaging changes.
Who should organise the compliance review?
The project should assign the importing or manufacturing business and local reviewer explicitly. The supplier can provide agreed technical inputs, while the responsible parties record the applicable conclusions.
Can the brand advertise treatment of a skin disease?
Medsafe states that therapeutic claims are not permitted for products supplied as cosmetics. Obtain a category and claims assessment before using disease-related presentation.
What should happen when the supplier changes an ingredient?
Apply the agreed change-control process before release. Reassess the affected formula, ingredient information, claims and packaging, and retain the revised decision with the commercial batch records.